Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Cervical Cancer”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 649 records · Page 36Linked to original sources
PubMed2000

Human papillomavirus infection and invasive cervical cancer in Paraguay.

HPV types 16 and 18 have been categorized as human carcinogens based on their strong associations with cervical cancer in previous case-control studies. Recent IARC studies in the Philippines, Thailand and Morocco show strong associations between invasive cervical cancer and less common HPV types, including HPV 31, 33, 45, 51, 52 and 58. We present results of a further IARC case-control study conducted in Asunción, Paraguay, to examine the association between specific HPV types and invasive cervical cancer as well as risk factors other than HPV. One-hundred thirteen incident histologically confirmed invasive cervical cancer cases and 91 age-matched hospital controls were recruited. A standardized questionnaire was administered to investigate known and suspected risk factors for cervical cancer. For HPV status determination, cervical biopsy specimens from case subjects and exfoliated cervical cells from control subjects were obtained. HPV DNA was ascertained using a GP5+/6+ PCR-based assay capable of detecting more than 33 HPV types. Overall HPV prevalence was 97% in the cervical cancer cases and 20% in the control subjects. As a single infection, HPV 16 was the predominant type with a prevalence of 48% among case subjects and 5.5% among control subjects. Significant associations with the risk of cervical cancer were detected as follows: any HPV type (OR = 114; 95% CI: 36-361); HPV 16 (OR = 910); HPV 18 (infinite OR); HPV 31 (OR = 110); HPV 33 (OR = 261); HPV 45 (OR = 129); and HPV 58 (OR = 36). In the multivariate model, risk factors other than HPV significantly associated with cervical cancer risk were a higher number of lifetime sexual partners, lower educational status and never having had a Pap smear. Strong associations were found between invasive cervical cancer and specific HPV types 16, 18, 31, 33, 45 and 58.

Adolescent↗
PubMed2002

Measurement of erythrocyte lipids, lipid peroxidation, antioxidants and osmotic fragility in cervical cancer patients.

BACKGROUND: Our aim was to examine the structural integrity of red blood cells in cervical cancer patients by measuring the concentrations of thiobarbituric acid reactive substances (TBARS), antioxidant status, cholesterol/phospholipid (C/P) molar ratio, enzyme activity and osmotic fragility of erythrocytes. METHODS: This study has been conducted on 32 adult female cervical cancer patients and an equal number of age- and sex-matched normal subjects. Erythrocyte concentrations of lipids, TBARS, vitamin E, reduced glutathione and enzymic activities of catalase and Na(+)K(+)-ATPase were measured as well as plasma concentrations of sodium and potassium. The present study also examined the changes in erythrocyte osmotic fragility in cervical cancer patients and normal subjects. The red cell fluidity and permeability were determined by estimating the C/P ratio and Na(+)K(+)-ATPase activity, respectively. RESULTS: The release of thiobarbituric acid reactive substances was significantly higher in cervical cancer patients as compared to normal subjects. The increased lipid peroxidation with concomitant decrease in antioxidants was notable in cervical cancer patients. Red blood cells of cervical cancer patients were more fragile than those from normal subjects. Increase in red cell membrane C/P ratio and Na(+)K(+)-ATPase activity was noticed in cervical cancer patients as compared to normal subjects. CONCLUSIONS: Increased lipid peroxidation, insufficient antioxidant potential and changes in C/P molar ratio as well as activity of Na(+)K(+)-ATPase cause structural and functional abnormalities in the erythrocytes of cervical cancer patients.

Adult↗
PubMedDate not supplied

Semiquantitative analysis of telomerase activity in cervical cancer and precancerous lesions.

We investigated telomerase expression in cervical lesions and its diagnostic value for cervical cancer and the precancerous lesions. The subjects were 100 women who underwent cervical biopsy, comprising 16 normal cervix, 61 cervical intraepithelial neoplasia (CIN) and 23 invasive cervical cancer. Telomerase activity was detected by the telomerase repeat amplification protocol using a non-radioisotope system, and quantitated using a DNA image analyzing system. Telomerase was detected at 18.8% (3/16) in normal cervix, 32. 0% (8/25) in CIN I, 50.0% (3/6) in CIN II, 60.0% (18/30) in CIN III, and 91.3% (21/23) in invasive cervical cancer. Semiquantitation of telomerase activity was significantly higher in the subjects with invasive cancer than in those with CIN or a normal cervix (p<0.05). However, telomerase activity was not significantly different between the grades of CIN. Telomerase was detected in subjects with CIN, suggesting that telomerase expression is an early event in cervical carcinogenesis. Quantitation of telomerase activity may be helpful for the diagnosis of cervical cancer.

Biopsy↗
PubMed2001

Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus.

OBJECTIVE: Many investigators have studied the expression of G1 phase regulatory protein in uterine cervical cancer. However, it is unclear which step of the genetic expression participates in cyclin D1 expression and what its prognostic meaning is. The aims of this study were to evaluate the regulatory level of cyclin D1 expression and the relationship between the expression of cyclin D1 and its inhibitor, p21WAF1/CIP1, and to evaluate their impact on the prognosis of early stage cervical cancer. METHODS: The presence of cyclin D1 mRNA was studied using Northern blot in 6 normal cervices and 7 invasive cervical cancer specimens. Western blot was used to detect the cyclin D1 protein in 8 normal cervices and 8 invasive cancer specimens. Thirty-two cases of FIGO stage Ib-IIa cervical cancers (28 squamous cell carcinomas, 3 adenocarcinomas, 1 adenosquamous cell carcinoma), 31 cases of cervical intraepithelial neoplasia 3 (CIN 3), and 28 normal cervices were stained for cyclin D1 and p21(WAF1/CIP1) using monoclonal antibody. Statistical analysis was performed to assess the differences in expression and their prognostic significance. RESULTS. Cyclin D1 mRNA was found to be underexpressed in cervical cancer. Western blot also revealed underexpression of cyclin D1 protein in cervical cancer compared to normal controls. Positive immunohistochemical staining of cyclin D1 was noted in 28/28 (100%) of the normal controls, 1/31 (3%) cases of CIN 3, and 9/32 (28%) cases of invasive cancer. The number of positively stained specimens was lower than that of normal controls in CIN 3 and cervical cancer specimens (P = 0.005). Fifteen of 28 (54%) normal controls, 15/31 cases (48%) of CIN 3, and 27/32 cases (84%) of invasive cancer were proved positive for p21WAF1/CIP1 immunohistochemistry. p21WAF1/CIP1 was more highly expressed in cervical cancer than in that of either normal controls or CIN specimens (P = 0.001). Positive immunostaining of cyclin D1 and p21WAF1/CIP1 was not related to high-risk factors (pelvic lymph node metastasis, deep cervical stromal invasion, parametrial invasion, large tumor size, and unusual histologic type) and human papilloma virus infection. Positive cyclin D1 immunostaining was associated with decreased disease-free survival and a lower overall survival (P = 0.0175 and 0.0189, respectively). On multivariate analysis, positive cyclin D1 expression was a significant prognostic variable for recurrence (P = 0.0004). CONCLUSION: Underexpression of cyclin D1 was regulated at the level of transcription in cervical cancer. Although cyclin D1 was underexpressed in cervical neoplasias, it was more frequently expressed in malignant lesions. p21WAF1/CIP1 was more highly expressed in cervical cancers than in either normal cervices or CIN 3 specimens. Unfavorable prognoses were associated with cyclin D1 expression, and not with the expression of its inhibitor, p21WAF1/CIP1.We conclude that immunohistochemical assessment of cyclin D1 can be a useful molecular marker for predicting prognosis in early stage cervical cancer of the uterus.

Blotting, Northern↗
PubMed1988

[Comparison of the clinical features of uterine cervical cancers detected by mass screening and voluntary visit].

In order to identify the characteristics of uterine cervical cancers detected by mass screenings (mass group), these cancers were compared to cancers diagnosed in patients voluntarily visiting medical institutions (voluntary group), and the following results were obtained. 1. The mass group tended to show a higher incidence of cervical cancer, and the voluntary group had a higher incidence of endometrial cancer. 2. In the mass group having cervical cancer, the age was younger than that in the voluntary group. Also the incidence of cancer among relatives within the third generation and the frequency of previous participating in a mass screening were both significantly greater (p less than 0.01), compared to the voluntary group. 3. As compared to the voluntary group, many patients in the mass group having cervical cancer were asymptomatic and were diagnosed at an early stage, and even if symptomatic, there still were more early cancers in the mass group than in the voluntary group (p less than 0.01). 4. The incidence of lymph node metastases in advanced cervical cancer, that is beyond stage I b, was lower in the mass group than in voluntary group (p less than 0.01). 5. Cervical cancers in the mass group were surgically treated in 94.2% of cases, and the rate was higher than that in the voluntary group. In the surgical treatment, 77.4% of cases in the mass group underwent a simple hysterectomy and a semi-radical hysterectomy, and the frequency of surgical treatment was higher than that in the voluntary group (p less than 0.01). There also was a tendency toward a shorter time of operative procedures, less bleeding during operation, and fewer postoperative complications. 6. In the mass group having cervical cancers, the prognosis was favorable (p less than 0.01). By the clinical stage, in early cancers including stage 0 and stage I a, there was no significant difference in the prognosis between the mass group and voluntary group, and in the advanced cancer, the prognosis was more favorable in the mass group compared to the voluntary group (p less than 0.01). Asymptomatic patients had a better prognosis than symptomatic patients, and there was no difference between the two groups, but among symptomatic patients the prognosis was more favorable in the mass group than in the voluntary group.

Adult↗
PubMed1978

[Epidemiology of cervical cancer (author's transl)].

There are remarkable differences of incidence and mortality from cervical cancer between countries and even within small countries. In developed industrial countries, incidence is slowly declining. Age distribution (middle--aged women are mostly afflicted) distinguishes cervical cancer from all other common malignant neoplasms. Known risk factors are: low social class, sexual activity early in youth, instable sexual relationships. Cervical cancer behaves like a veneral disease of low infectious power. Cervical cancer develops stepwise out of epithelial dysplasia and carcinoma in situ. The foundations of a cervical cancer control programme are laid: cytodiagnosis as screening method; well defined high risk groups; effective and not dangerous treatment of prephases and early stages of cancer. In the G.D.R. conditions for effective cancer control are good: cancer registration works stable for more than 20 years; it enables evaluation of effectivity. Cytologic screening can be fully integrated into basic gynecologic care. Medical care including prevention is free of fees and available for all women. The ultimate of goal of a cervical cancer control programme is primary prevention by detection and treatment of preneoplastic lesions (dysplasia and carcinoma in situ).

Adolescent↗
PubMed2006

Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer.

BACKGROUND: The aim of this study was to evaluate epigenetic status of cyclin A1 in human papillomavirus-associated cervical cancer. Y. Tokumaru et al., Cancer Res 64, 5982-7 (Sep 1, 2004)demonstrated in head and neck squamous-cell cancer an inverse correlation between cyclin A1 promoter hypermethylation and TP53 mutation. Human papillomavirus-associated cervical cancer, however, is deprived of TP53 function by a different mechanism. Therefore, it was of interest to investigate the epigenetic alterations during multistep cervical cancer development. METHODS: In this study, we performed duplex methylation-specific PCR and reverse transcriptase PCR on several cervical cancer cell lines and microdissected cervical cancers. Furthermore, the incidence of cyclin A1 methylation was studied in 43 samples of white blood cells, 25 normal cervices, and 24, 5 and 30 human papillomavirus-associated premalignant, microinvasive and invasive cervical lesions, respectively. RESULTS: We demonstrated cyclin A1 methylation to be commonly found in cervical cancer, both in vitro and in vivo, with its physiological role being to decrease gene expression. More important, this study demonstrated that not only is cyclin A1 promoter hypermethylation strikingly common in cervical cancer, but is also specific to the invasive phenotype in comparison with other histopathological stages during multistep carcinogenesis. None of the normal cells and low-grade squamous intraepithelial lesions exhibited methylation. In contrast, 36.6%, 60% and 93.3% of high-grade squamous intraepithelial lesions, microinvasive and invasive cancers, respectively, showed methylation. CONCLUSION: This methylation study indicated that cyclin A1 is a potential tumor marker for early diagnosis of invasive cervical cancer.

Biomarkers, Tumor↗
PubMed2003

Apoptotic activity in lymphocytes from radiation-treated cervical cancer patients.

PURPOSE: The per cent apoptotic activity in lymphocytes from pre-treated cervical cancer patients was cross-sectionally compared with post-treated patients at 1 month, 3 months, 1 year, and 5 years after completing the standard radiation therapeutic regimen. In addition, the differences in the per cent apoptotic activities among various stages of cervical cancer were simultaneously analyzed. MATERIAL AND METHOD: Blood samples were collected from five patients in each stage of cervical cancer before treatment, and at 1 month, 3 months, 1 year, and 5 years after completing the radiation therapy. The control samples were collected from healthy and aged-match female blood donors. The lymphocytes were separated and exposed to 0.5 Gy Co irradiation to induce apoptosis. The apoptotic cells were detected by in situ terminal deoxynucleotidyl transferase (TdT assay) and counted under a fluorescent microscope. Both the apoptotic index and per cent apoptotic activity were calculated. RESULTS: The per cent apoptotic activities in lymphocytes from all pre-treated patients with stage II and III cervical cancer were significantly lower than the controls (p = 0.001). The apoptotic activity in normal control, however, was not significantly different from the pre-treated stage I cervical cancer group. Following radiation therapy, the apoptotic activities at 1 month, 3 month and 1 year were increased in all stages. The per cent apoptotic activity, in all stages of cervical cancer at 5 years after treatment, was statistically higher than that of the pre-treated groups. CONCLUSION: There was a decrease of per cent apoptotic activity in lymphocytes from all pre-treated cervical cancer patients in the present study, the change of which was reversed to normal after treatment in non-recurrent cases.

Adult↗
PubMed2006

General practitioners' perception of risk factors for cervical cancer development: consequences for patient education.

OBJECTIVE: The introduction of human papillomavirus (HPV) detection in cervical screening will make it necessary to provide appropriate information to the general public. Only 3% of Flemish women could name HPV as the viral agent involved in cervical cancer development. The aim of this study was to investigate whether general practitioners (GPs) have appropriate knowledge of the relationship between HPV and cervical cancer to be able to inform women. METHODS: A questionnaire was developed to measure perception of 20 risk factors for cervical cancer development, on a scale of 1 (unimportant) to 5 (very important). Respondents were also asked to give an estimate of the chances of survival for women, diagnosed with cervical cancer detected by screening. RESULTS: Sixty GPs and 28 trainees filled in the questionnaire. The five most important risk factors in the perception of the respondents were, in order of decreasing importance, viral infection, number of sex partners, sexual behaviour of the partner, unsafe sex, and early start of sexual activity. Fifty-six percent of the GPs expected the chance of survival to be between 80 and 100%, compared to only 31% of the trainees. CONCLUSION: Most GPs are well aware of sexual habits as risk factors for cervical cancer development, including the role of HPV as the viral agent in the etiology. However, they seem to underestimate the role of smoking and are unable to identify the correct chance of survival for women in whom cervical cancer is detected within the frame of the cervical smear program. PRACTICE IMPLICATIONS: Attention should be given to education of medical students and practitioners, in order to allow them to supply patients with sufficient background information to make an informed choice on participating in cervical cancer screening.

Attitude of Health Personnel↗
PubMed1995

Sexual behavior, sexually transmitted diseases, and risk of cervical cancer.

To explore sexually transmitted diseases and sexual behavior as risk factors for cervical cancer, we analyzed data from a population-based case-control study of breast and cervical cancer in Costa Rica. Data from 415 cases of cervical carcinoma in situ, 149 cases of invasive cervical cancer, and 764 controls were included in the analysis. Multivariate analysis showed that lifetime number of sex partners, first intercourse before age 15 years, number of livebirths, herpes simplex virus type 2 seropositivity, and serologic evidence of previous chlamydial infection were predictors of carcinoma in situ. Serologic evidence of previous syphilis was not associated with carcinoma in situ. Predictors for invasive cervical cancer included lifetime number of sex partners, first intercourse before age 15 years, number of livebirths, serologic evidence of previous syphilis, herpes simplex type 2 infection, and chlamydial infection. Cigarette smoking, socioeconomic status, self-reported history of sexually transmitted diseases, and douching were not associated with either carcinoma in situ or invasive cervical cancer.

Adult↗
PubMed2002

HIV and cervical cancer in Kenya.

OBJECTIVES: To determine the effect of the HIV epidemic on invasive cervical cancer in Kenya. METHODS: Of the 3902 women who were diagnosed with reproductive tract malignancies at Kenyatta National Hospital (KNH) from 1989 to 1998, 85% had invasive cervical cancer. Age at presentation and severity of cervical cancer were studied for a 9-year period when national HIV prevalence went from 5% to 5-10%, to 10-15%. RESULTS: There was no significant change in either age at presentation or severity of cervical cancer. Of the 118 (5%) women who were tested for HIV, 36 (31%) were seropositive. These women were 5 years younger at presentation than HIV-negative women. CONCLUSIONS: A two- to three-fold increase in HIV prevalence in Kenya did not seem to have a proportional effect on the incidence of cervical cancer. Yet, HIV-positive women who presented with cervical cancer were significantly younger than HIV-negative women.

Adenocarcinoma↗
PubMed2006

Organization of cervical cancer screening in Campinas and surrounding region, São Paulo State, Brazil.

Cervical cancer screening remains a challenge in developing countries due to a complex array of problems. This paper aimed to describe the experience with organization of cervical cancer screening in three districts of Campinas and the surrounding region in São Paulo State, Brazil, and to report the resulting data. The program was organized in a pyramid format, and the health care hierarchy was defined according to the complexity and total number of medical procedures. Screening has been extended currently to 88 municipalities, of which 51 are equipped with colposcopy and eight have facilities for treating advanced cervical cancer. The standardized incidence rate for cervical cancer in Campinas was 14.2/100,000 women per year in 1993-1995, and the standardized mortality rate per district ranged from 2.7 to 3.0 per 100,000 women in 1997-1998. This project has clearly shown that hierarchical and decentralized organization of health procedures is a necessary condition for achieving the goals of an effective cervical cancer screening program.

Brazil↗
PubMed1992

An audit of cervical cancer deaths in Nottingham.

Death certificates were reviewed and 57 women were identified whose primary cause of death was cervical cancer. Their cervical smear records were reviewed from laboratory files. Only nine had participated in the cervical cancer screening programme before the diagnosis of cervical cancer was made. One woman had an abnormal smear as a result of cervical screening but failed to attend for follow-up. The problem of false negative smears is also addressed and the value of review of negative smears for the purposes of cytology audit is emphasized.

Adult↗
PubMed1992

Reaching special populations with breast and cervical cancer public education.

With passage of the Breast and Cervical Cancer Mortality Prevention Act of 1990, significant activity has emerged in the development, implementation, and evaluation of breast and cervical cancer screening programs targeting underserved populations. This activity has prompted health educators and program planners to identify barriers to breast and cervical cancer screening specific to low-income and minority women, those traditionally underserved by cancer control programs, and to develop strategies that address these barriers. The authors reviewed current knowledge regarding barriers to breast and cervical cancer screening and public education interventions that address them. The results and implications for program planning activities are presented.

Adult↗
PubMed1996

Cervical cancer screening in an urban population in Taiwan: five-year results.

OBJECTIVE: To review the first five years of the educational and cervical cancer screening program (ECCSP) at twelve public health centers in the metropolitan area of Taipei and to measure whether the ECCSP had an impact on cancer patterns. METHODS: We used data for cervical cancers diagnosed between 1986 and 1991 from all hospitals in Taipei and from the national cancer registry. During this time period, 2 158 cervical cancers were diagnosed from thirty-nine hospitals in Taipei city, of which 5% were identified after referral from the ECCSP: RESULTS: The percentage of early cervical cancers, defined as stage 0 or Ia, was 70% in women referred from the ECCSP, compared with 20% for women who were not referred from the ECCSP (P < 0.001). All age groupings also demonstrated this similar difference. The case-fatality rate of cervical cancer was significantly lower for ECCSP referred patients (8 of 106, 7.5%) than for non-ECCSP referred patients (401 of 2 051, 19.6%) during this study period (P < 0.01). CONCLUSIONS: This information suggests that the ECCSP has had a remarkable impact on the early diagnosis of cervical cancer. It is expected that a well organized screening program will be applied to a large target population from young to old adults so that the program can be effective for reducing the mortality rate of cervical cancer in Taiwan.

Adult↗
PubMed2005

HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.

OBJECTIVES: The specific CTL response against human papillomavirus (HPV) antigens in women with cervical cancer has been poorly studied. Immunological monitoring of this response is central for understanding the principles that underlie successful immunotherapeutic strategies. The aim of the study was to investigate the HPV16 E6/E7-specific CTL immune response in a group of untreated HPV16-positive cervical cancer patients. METHODS: Peripheral blood mononuclear cells from 21 untreated cervical cancer patients and 4 healthy controls were isolated prior to any therapy. Autologous monocyte-derived dendritic cells (MDDCs) were transiently transfected with HPV16 E6 or E7 expression vectors and used for one round of in vitro restimulation and as target cells in chromium release assays with restimulated peripheral blood lymphocytes. RESULTS: Transfected monocyte-derived dendritic cells were differentiated to exhibit a fully mature phenotype. HPV16 E6 and E7 transgenes were expressed and translated as measured by RT-PCR and intracellular flow cytometry, respectively. All HPV16-associated cervical cancer patients showed evidence of specific CTLs. Lytic activity for HPV16 E6 (11/12) and/or E7 (8/9) was above 30% at the 100:1 effector to target ratio. None of the HPV16-negative cervical cancer patients or healthy controls were above 15% of lysis. CONCLUSIONS: These data suggest that HPV-specific cytolytic immune responses can be detected in all untreated cervical cancer patients. Our approach, using dendritic cells for restimulation and as target cells, may enhance immunomonitoring of cervical cancer patients.

Dendritic Cells↗
PubMed2005

[Effect of 2-methoxyestradiol on human cervical cancer cells HeLaS3 and xenografts].

OBJECTIVE: To evaluate the effects of 2-methoxyestradiol (2-ME(2)) on human cervical cancer HeLaS3 cells and cervical cancer xenografts. METHODS: Cell proliferation assay and cell cycle analysis were used to measure HeLaS3 cell growth and cell cycle progression after 2-ME(2) treatment. Fluorescent microscopy to observe the cell morphology and DNA electrophoresis to measure apoptosis. In addition, the effect of 2-ME(2) on the expression of inducible nitric oxide synthase (iNOS) was measured by Western blot. Moreover, human cervical cancer model was set up using HeLaS3 cells and 2-ME(2) (75 mg/kg) was orally given for 14 d. Tumor volume was determined and apoptosis was detected by in situ cell death. RESULTS: Newly-formed cell amount in treated group was 81% of that in control group after 1 micromol/L 2-ME(2) treatment for 48 h (P < 0.05), and was 19% of that in control group after 2-ME(2) treatment for 96 h (P < 0.01). G(2)/M phase cells were increased to 55% from 16% of the control (P < 0.01), and apoptotic cells were increased to 16% from 4% of the control, after 5 micromol/L 2-ME(2) treatment for 20 h. Nuclear condensation and abnormal metaphase cells were found by fluorescent microscopy. Typical DNA ladder was found by DNA electrophoresis. And the expression of iNOS was increased by 2-ME(2) in a time- and concentration-dependent manner, in parallel with apoptosis. Moreover, apoptosis was prevented by the iNOS inhibitor 1400W. In vivo, tumor volume was reduced 34% while compared with the control group. In situ cell death detection found more apoptotic and necrotic cells in 2-ME(2)-treated group. CONCLUSIONS: 2-ME(2) inhibits human cervical cancer HeLaS3 cells and tumor growth in cervical cancer xenografts. Thus 2-ME(2) has the therapeutic potential for cervical carcinoma.

2-Methoxyestradiol↗
PubMed1996

Update: National Breast and Cervical Cancer Early Detection Program--July 1991-September 1995.

During the 1990s, breast or cervical cancer will be diagnosed in an estimated 2 million women in the United States, and 500,000 will die as a result of these diseases. Screening mammography followed by timely and appropriate treatment can reduce breast cancer mortality by 30% for women aged 50-69 years, and routine use of the Papanicolaou (Pap) test followed by timely and appropriate treatment can prevent nearly all deaths from cervical cancer. The Breast and Cervical Cancer Mortality Prevention Act of 1990 established a nationwide, comprehensive public health program for increasing access to breast and cervical cancer screening services for underserved women. This report summarizes the impact of this initiative, CDC's National Breast and Cervical Cancer Early Detection Program (NBCCEDP), during July 1991-September 1995.

Breast Neoplasms↗